bluuebunny/crossref_metadata_2025_split huggingface dataset:
The effectiveness of parenteral agents for pain reduction in patients with migraine presenting to emergency settings: A systematic review and network analysis
Authors: Kirkland Scott W. , Visser Lloyd , Meyer Jillian , Junqueira Daniela R. , Campbell Sandra , Villa‐Roel Cristina , Friedman Benjamin W. , Essel Nana Owusu , Rowe Brian H. 
Published: April 2024

AbstractObjectivesTo assess the comparative effectiveness and safety of parenteral agents for pain reduction in patients with acute migraine.BackgroundParenteral agents have been shown to be effective in treating acute migraine pain; however, the comparative effectiveness of different approaches is unclear.MethodsNine electronic databases and gray literature sources were searched to identify randomized clinical trials assessing parenteral agents to treat acute migraine pain in emergency settings. Two independent reviewers completed study screening, data extraction, and Cochrane risk‐of‐bias assessment, with differences being resolved by adjudication. The protocol of the review was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42018100096).ResultsA total of 97 unique studies were included, with most studies reporting a high or unclear risk of bias. Monotherapy, as well as combination therapy, successfully reduced pain scores prior to discharge. They also increased the proportion of patients reporting pain relief and being pain free. Across the pain outcomes assessed, combination therapy was one of the higher ranked approaches and provided robust improvements in pain outcomes, including lowering pain scores (mean difference −3.36, 95% confidence interval [CI] −4.64 to −2.08) and increasing the proportion of patients reporting pain relief (risk ratio [RR] 2.83, 95% CI 1.74–4.61). Neuroleptics and metoclopramide also ranked high in terms of the proportion of patients reporting pain relief (neuroleptics RR 2.76, 95% CI 2.12–3.60; metoclopramide RR 2.58, 95% CI 1.90–3.49) and being pain free before emergency department discharge (neuroleptics RR 4.8, 95% CI 3.61–6.49; metoclopramide RR 4.1, 95% CI 3.02–5.44). Most parenteral agents were associated with increased adverse events, particularly combination therapy and neuroleptics.ConclusionsVarious parenteral agents were found to provide effective pain relief. Considering the consistent improvements across various outcomes, combination therapy, as well as monotherapy of either metoclopramide or neuroleptics are recommended as first‐line options for managing acute migraine pain. There are risks of adverse events, especially akathisia, following treatment with these agents. We recommend that a shared decision‐making model be considered to effectively identify the best treatment option based on the patient's needs.
Challenges in the management of new daily persistent headache at a tertiary headache center—A retrospective real‐world evidence study
Authors: Linnet Thor , Hussein Marwa , Schytz Henrik Winther , Bendtsen Lars , Amin Faisal Mohammad 
Published: April 2024

AbstractObjectiveIn this retrospective cross‐sectional real‐world evidence study from the Danish Headache Center (DHC), a national tertiary headache center in Denmark, we sought to identify potential pharmacological agents for the treatment of new daily persistent headache (NDPH).BackgroundNDPH is an enigmatic headache disorder with abrupt onset and chronic duration for which evidence‐based treatments are lacking. NDPH is a diagnosis of exclusion, for which secondary headaches must be ruled out and the etiology remains idiopathic. The sparse investigations of this disorder have not yielded a pathophysiological basis and no effective treatment for NDPH has been found.MethodsAll patients with an NDPH diagnosis at the DHC were enrolled (n = 64). First, we reviewed the records of all patients with an NDPH diagnosis to evaluate whether they fulfilled the diagnostic criteria. Next, we extracted all the trialled acute and prophylactic pharmacological interventions for the included patients. Then, pharmacological interventions that had been tried in ≥ 20 patients were analyzed post hoc with efficacy as the outcome, which was stratified in five effect categories (“no effect,” “partial effect,” “full effect,” “partial effect and cessation due to adverse events,” and “full effect and cessation due to adverse events”). Descriptive statistical analysis was performed, and the results were schematically presented (see Table 2).ResultsFifty‐one patients out of 64 were found to fulfill NDPH criteria and were included in the study. The drugs tried by ≥ 20 patients were amitriptyline (n = 34), candesartan (n = 27), and mirtazapine (n = 20). No patients experienced a complete effect with these drugs while 9% (3/34), 26% (7/27), and 15% (3/20) experienced a partial effect with no adverse events that led to treatment discontinuation, respectively. The remaining patients experienced either no effect or a partial effect with adverse events leading to treatment discontinuation.ConclusionIn this study we add real‐world evidence to suggest that prophylactic drugs conventionally used for treating chronic migraine and chronic tension‐type headache have limited utility for treating NDPH; however, a partial response in 26% of patients using candesartan and 15% of patients using mirtazapine warrants further investigation in randomized double‐blinded placebo‐controlled trials.
Real‐world use of long‐acting cabotegravir and rilpivirine: 12‐month results of the inJectable Antiretroviral therapy feasiBility Study (JABS)
Authors: John M. , Williams L. , Nolan G. , Bonnett M. , Castley A. , Nolan D. 
Published: April 2024

AbstractObjectivesThe inJectable Antiretroviral feasiBility Study (JABS) aimed to evaluate the implementation of long‐acting regimens in a ‘real world’ Australian setting, with inclusion of participants with complex medical needs, social vulnerability and/or historical non‐adherence.MethodsJABS was a 12‐month, single‐centre, single‐arm, open‐label phase IV study of long‐acting cabotegravir 600 mg plus rilpivirine 900 mg administered intramuscularly every 2 months to adults with treated HIV‐1 infection. The primary endpoint was the proportion of attendances and administration of injections within a 14‐day dosing window over 12 months, out of the total prescribed doses. Secondary endpoints included proportions of missed appointments, use of oral bridging, discontinuations, virological failures, adverse events and participant‐reported outcomes. A multidisciplinary adherence programme embedded in the clinical service known as REACH provided support to JABS participants.ResultsOf 60 participants enrolled by May 2022, 60% had one or more complexity or vulnerability factors identified, including absence of social supports (50%), mental health issues, alcohol or drug use (30%) and financial hardship or instability (13%), among others. Twenty‐seven per cent of participants had historical non‐adherence to antiretroviral therapy. Out of 395 prescribed doses, 97.2% of injections were administered within correct dosing windows at clinic visits. Two courses of short‐term oral bridging were required. The rate of injection site reactions was 29%, the majority being grade 1–2. There were no virological failures, no serious adverse events and only one injection‐related study discontinuation. High baseline treatment satisfaction and acceptability of injections increased by month 12. Those with vulnerability factors had similar adherence to injections as those without such factors. Ninety‐eight per cent of the participants who completed 12 months on the study have maintained long‐acting therapy, virological suppression and retention in care.ConclusionsLong‐acting cabotegravir plus rilpivirine was associated with very high adherence, maintenance of virological suppression, safety and treatment satisfaction in a diverse Australian clinic population, comparable to results of phase III randomized clinical trials. Individuals with vulnerability factors can achieve adherence to injections with individualized support. Long‐acting therapies in this group can increase the subsequent engagement in clinical care.
Recent advances in rapid and reliable biosensors for detection of porcine gelatine
Authors: Sari Rizki Muharami Cedia , Wyantuti Santhy , Zein Muhammad Ihda H.L. , Rahimah Souvia , Irkham Irkham , Ibrahim Abdullahi Umar , Ozsoz Mehmet , Hartati Yeni Wahyuni 
Published: April 2024

SummaryGelatine is obtained from the hydrolysis of collagen in bones, skin, fins, fish scales and insect bodies of cattle, pigs, camels, poultry, fish and insects. Consequently, the diversity and availability of gelatine sources, along with gelatine authentication, are concerns for those consuming gelatine products from religious, health and economic perspectives. Therefore, rapid and reliable protein‐ or DNA‐based detection methods have been developed for gelatine authentication. This review discusses and evaluates biosensor methods, comparing them with various analytical methods in terms of their popularity and precision. Additionally, the development of biosensor methods has been explored to identify a reference for a rapid, accurate, portable and simple method for gelatine detection with a low detection limit and high specificity.
Development of a yeast‐free bread using legume and nut flours in a gluten‐free flour: Techno‐functional characteristics and sensory evaluation
Authors: Tuna Ayca , Ortiz‐Solà Jordi , López‐Mas Laura , Baser Filiz , Kallas Zein , Aguiló‐Aguayo Ingrid , Gulec Sukru , Ozen Banu , Tokatli Figen 
Published: April 2024

SummaryThis study aimed to investigate the effect of combined use of legume and nut flours on physical, nutritional and sensory properties of yeast‐free bread by substituting gluten‐free flour with hazelnut and white bean flours. Yeast‐free bread containing a mixture of 30% hazelnut and white bean flours was found to have the lowest hardness (9.04 N) and the largest specific volume (1.51 mL g−1) compared to the reference gluten‐free bread (18 N and 1.43 mL g−1) using a mixture design. Hazelnut and bean flours improved the in vitro starch digestion, reducing rapidly digestible starch by 29% and increasing resistant starch compared to the reference bread. Free choice profiling sensory analysis revealed that the developed breads containing nuts and legumes differed from the standard gluten‐free formulation and a commercial product available on the market. The combined use of bean and hazelnut flours was demonstrated as functional ingredients for enhancement of nutritional, sensory and textural aspects.
60Co γ‐radiation at low‐dose level alters volatile compounds of blueberry during storage
Authors: Liu Dongjie , Liu Zhen , Lan Bifeng , Ma Lukai , Huang Hua , Xiao Gengsheng , Wang Qin , Wang Feng 
Published: April 2024

Summary60Co γ‐radiation was applied to blueberry fruits in an effort to investigate a safe, eco‐friendly and effective blueberry preservation technique. However, the preservation effects were variable depending on tissue tolerance to irradiation doses. Moreover, irradiation may cause off‐odour. In this study, we examined the effects of three low doses of 60Co γ‐radiation on the physical and flavour attributes of blueberry. The results showed that 60Co γ‐radiation did not significantly improve fruit quality but extend the shelf life up to 15 days at 25 °C and 30 days at 4 °C. Compared with the control group, the preservation effect of 0.5–1.0 kGy irradiation treatment on blueberry fruit was not obvious before 15 days but maintained 65% of fruit firmness and reduced the loss of nutrients afterwards at 4 °C. At 25 °C, irradiation treatment caused up to a 150% increase in polyphenol oxidase activity, which was relevant to colour changes in late storage. Headspace Gas Chromatography Ion Mobility Spectrometry (HS‐GC‐IMS) was applied, and 33 volatile organic compounds (VOCs) in blueberry treated with different radiation doses were identified, including 11 esters, 8 aldehydes, 7 alcohols, 6 ketones and other substances, which increased with increasing radiation dose. Radiation reduced the green taste of blueberry and promoted their ripening. Radiation above the level of 1.02 kGy led to the flavour deterioration of blueberry such as ethyl trans‐2‐butenoate. The side effects of radiation on the aroma of blueberry could be offset by low‐temperature storage. Blueberry stored at 4 °C contained more aldehydes with a heavier fresh/green aroma. Six aromas were proposed to be characteristic odour markers of radiated blueberry.
New method to differentiate between lupus anticoagulants, progressive coagulation inhibitors and coagulation factor deficiencies in the mixing tests
Authors: Shimomura Daiki , Kumano Osamu , Ueda Kaori , Kitano Keisuke , Arai Nobuo , Shimada Masashi , Kamioka Mikio 
Published: April 2024

AbstractIntroductionMixing tests in activated partial thromboplastin time (APTT) are used for the differentiation between lupus anticoagulants (LA), coagulation inhibitors, and factor deficient samples with APTT prolongation. However, the indexes for the differentiation have not been established. The present study aimed to develop new mixing test indexes for the differentiation.MethodsTwenty‐six LA‐positive, 8 progressive coagulation factor VIII inhibitor, and 35 coagulation deficient samples were employed. APTT were measured for normal plasma, patient plasma, and mixing plasma prepared at a ratio of 1:1 proportion in both without incubation and 2 h‐incubation. New two parameters named as ALD50 and mixture plasma—patient plasma after Warming change rate Subtraction (WaS) calculated from the clotting times of normal, 1:1 mixing and patient samples with/without 2 h‐incubation were established. In the samples with WaS result of <10.2%, ALD50 of ≥87.8%, and < 87.8% were defined as LA and coagulation factor deficiency, respectively, and WaS of ≥10.2% defined progressive coagulation factor inhibitors.ResultsSensitivity and specificity to LA were 80.8% and 93.0% for ALD50, and sensitivity and specificity to progressive coagulation factor inhibitor were 100.0% and 100.0% for WaS, respectively. The agreement between sample classification and WaS‐ALD50 was 88.4% (61/69).ConclusionsALD50 and WaS showed acceptable sensitivity and specificity to LA and progressive coagulation factor inhibitor, respectively. These indexes would be useful for the differentiation between LA, factor deficiency, and progressive coagulation factor inhibitor in the mixing tests.
Bricker versus Wallace ureteroileal anastomosis: A multi‐institutional propensity score‐matched analysis
Authors: Al‐Nader Mulham , Krafft Ulrich , Hess Jochen , Kesch Claudia , AbdelRazek Mostafa , Abolyosr Ahmad , Alsagheer Gamal A. , Mohamed Omar , Fathi Atef , Tschirdewahn Stephan , Hadaschik Boris A. , Mahmoud Osama 
Published: April 2024

Aim of the studyThe aim of our study is to evaluate the difference in stricture rate between matched groups of Bricker and Wallace techniques for ureteroileal anastomosis.Patients and methodsA retrospective analysis of patients undergoing urinary diversion (UD) with Bricker and Wallace ureteroileal anastomosis at two university hospitals. Two groups of Bricker and Wallace patients were matched in a 1:1 ratio based on the age, sex, body mass index (BMI), Charlson comorbidity index (CCI), preoperative hydronephrosis, prior radiation therapy or abdominal surgery, pathologic T and N stages and 30‐days‐Clavien grade complications≥III. A multivariable Cox regression analysis was conducted to identify predictors of ureteroenteric stricture (UES) in all patients.ResultsOverall, 740 patients met the inclusion criteria and 209 patients in each group were propensity matched. At a similar median follow‐up of 25 months, UES was detected in 25 (12%) and 30 (14.4%) patients in Bricker and Wallace groups, respectively (p = 0.56). However, only one patient in the Bricker group developed a bilateral stricture compared to 15 patients in the Wallace group, resulting in a significantly higher number of affected renal units in the Wallace group: 45 (10.7%) versus only 26 (6.2%) in the Bricker group (p = 0.00). On multivariable extended Cox analysis, prior radiotherapy, presence of T4 pelvic malignancy and nodal positive disease were independent predictor of UES formation.ConclusionThe technique of ureteroileal anastomosis itself does not increase the rate of stricture; however, conversion of two renal units into one is associated with a higher incidence of bilateral upper tract involvement.
Modulation of intestinal epithelial permeability by chronic small intestinal helminth infections
Authors: Mules Thomas C , Tang Jeffry S , Vacca Francesco , Yumnam Bibek , Schmidt Alfonso , Lavender Brittany , Maclean Kate , Noble Sophia‐Louise , Waugh Craig , van Ginkel Roel , Camberis Mali , Le Gros Graham , Inns Stephen 
Published: April 2024

AbstractIncreased permeability of the intestinal epithelial layer is linked to the pathogenesis and perpetuation of a wide range of intestinal and extra‐intestinal diseases. Infecting humans with controlled doses of helminths, such as human hookworm (termed hookworm therapy), is proposed as a treatment for many of the same diseases. Helminths induce immunoregulatory changes in their host which could decrease epithelial permeability, which is highlighted as a potential mechanism through which helminths treat disease. Despite this, the influence of a chronic helminth infection on epithelial permeability remains unclear. This study uses the chronically infecting intestinal helminth Heligmosomoides polygyrus to reveal alterations in the expression of intestinal tight junction proteins and epithelial permeability during the infection course. In the acute infection phase (1 week postinfection), an increase in intestinal epithelial permeability is observed. Consistent with this finding, jejunal claudin‐2 is upregulated and tricellulin is downregulated. By contrast, in the chronic infection phase (6 weeks postinfection), colonic claudin‐1 is upregulated and epithelial permeability decreases. Importantly, this study also investigates changes in epithelial permeability in a small human cohort experimentally challenged with the human hookworm, Necator americanus. It demonstrates a trend toward small intestinal permeability increasing in the acute infection phase (8 weeks postinfection), and colonic and whole gut permeability decreasing in the chronic infection phase (24 weeks postinfection), suggesting a conserved epithelial response between humans and mice. In summary, our findings demonstrate dynamic changes in epithelial permeability during a chronic helminth infection and provide another plausible mechanism by which chronic helminth infections could be utilized to treat disease.
Relative Effectiveness of the MF59®‐Adjuvanted Influenza Vaccine Versus High‐Dose and Non‐Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019–2020 US Influenza Season
Authors: Imran Mahrukh , Puig‐Barbera Joan , Ortiz Justin R. , Lopez‐Gonzalez Lorena , Dean Alex , Bonafede Machaon , Haag Mendel D. M. 
Published: April 2024

ABSTRACTBackgroundAdults ≥ 65 years of age have suboptimal influenza vaccination responses compared to younger adults due to age‐related immunosenescence. Two vaccines were specifically developed to enhance protection: MF59‐adjuvanted trivalent influenza vaccine (aIIV3) and high‐dose egg‐based trivalent influenza vaccine (HD‐IIV3e).MethodsIn a retrospective cohort study conducted using US electronic medical records linked to claims data during the 2019–2020 influenza season, we compared the relative vaccine effectiveness (rVE) of aIIV3 with HD‐IIV3e and a standard‐dose non‐adjuvanted egg‐based quadrivalent inactivated influenza vaccine (IIV4e) for the prevention of cardiorespiratory hospitalizations, including influenza hospitalizations. We evaluated outcomes in the “any” diagnosis position and the “admitting” position on the claim. A doubly robust methodology using inverse probability of treatment weighting and logistic regression was used to adjust for covariate imbalance. rVE was calculated as 100 * (1 − ORadjusted).ResultsThe study included 4,299,594 adults ≥ 65 years of age who received aIIV3, HD‐IIV3e, or IIV4e. Overall, aIIV3 was associated with lower proportions of cardiorespiratory hospitalizations with diagnoses in any position compared to HD‐IIV3e (rVE = 3.9% [95% CI, 2.7–5.0]) or IIV4e (9.0% [95% CI, 7.7–10.4]). Specifically, aIIV3 was more effective compared with HD‐IIV3e and IIV4e in preventing influenza hospitalizations (HD‐IIV3e: 9.7% [95% CI, 1.9–17.0]; IIV4e: 25.3% [95% CI, 17.7–32.2]). Consistent trends were observed for admitting diagnoses.ConclusionRelative to both HD‐IIV3e and IIV4e, aIIV3 provided improved protection from cardiorespiratory or influenza hospitalizations.
How many blood pressure measurements should we take in the office?
Authors: Özkan Gülsüm , Ulusoy Şükrü , Yılmaz Rahmi , Değer Serpil Müge , Derici Ülver , Arınsoy Turgay , Erdem Yunus ,   Turkish Society of Hypertension and Renal Diseases
Published: April 2024

AbstractNo consensus has emerged among different guidelines concerning how many blood pressure (BP) measurements should be performed at office visits in the diagnosis of hypertension. The purpose of this study was to examine the compatibility of various multiple average office BP measurements and 24‐h BP monitoring (ABPM) in patients followed up in the posthoc analysis of the Cappadocia hypertension cohort. A total 1158 office BP measurements by 207 patients were examined. The results were then classified as G1 (average of the 1st and 2nd BP), G2 (average of the 2nd and 3rd), G3 (average of the 2nd, 3rd, and 4th), G4 (average of the 2nd, 3rd, 4th, and 5th), and G5 (average of all five measurements). Compatibility between the average values in the groups and concomitant 24‐h ABPM data was examined. While a significant difference was observed between daytime 24‐h ABPM SBP and G1 (p = .002), no difference was found in the other groups. Office DBP approached the daytime 24‐h ABPM values as the number of measurements in the five groups increased, although average office DBP data in all groups were higher than daytime 24‐h ABPM DBP (p = .000 for all). In light of our study results, we recommend that three office BP measurements be performed and that the average of the 2nd and 3rd measurements be used for SBP, while in terms of DBP, we recommend that as many measurements as possible be taken without the 1st value being included in the average.